Atea (AVIR) CCO granted 119,520 stock options and adds shares

Q: What insider transactions did Atea Pharmaceuticals (AVIR) report for John Vavricka?

Atea’s Chief Commercial Officer John Vavricka acquired 42,083 common shares from RSU settlements and had 11,570 shares withheld for taxes at $4.24. He also received 119,520 new stock options and now holds common stock both directly and through a personal trust.

Q: How many Atea (AVIR) shares does John Vavricka own after this Form 4?

After the reported transactions, John Vavricka directly owns 82,594 Atea common shares . In addition, he indirectly holds 82,508 shares as trustee of the John F. Vavricka Deed of Trust, giving him significant combined exposure to Atea’s equity.

Q: What stock options did Atea’s CCO receive according to this Form 4?

The filing shows Vavricka was granted 119,520 stock options with a $4.24 exercise price. These options vest in 48 equal monthly installments following January 31, 2026, and will be fully vested by January 31, 2030, aligning incentives over a multi-year period.

Q: How do the new Atea stock options for Vavricka vest over time?

The 119,520 stock options vest in forty-eight equal monthly installments after January 31, 2026. According to the filing, this means the grant becomes fully exercisable on January 31, 2030, creating a long-term incentive structure for Atea’s Chief Commercial Officer.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Atea Pharmaceuticals Chief Commercial Officer John Vavricka reported several equity transactions in the company’s stock. On January 31, 2026, he acquired 42,083 shares of common stock through the vesting and settlement of restricted stock units.

To cover tax obligations, 11,570 shares of common stock were withheld at a price of $4.24 per share, leaving him with 82,594 directly held shares. He also holds 82,508 shares indirectly as trustee of the John F. Vavricka Deed of Trust.

On the same date, Vavricka received a new grant of 119,520 stock options with a $4.24 exercise price. These options vest in 48 equal monthly installments after January 31, 2026 and will be fully vested by January 31, 2030.

Insider Trade Summary

Net Buyer: 30,513 shares

Net Buy 6 txns

Insider Vavricka John

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	33,333	$0.00	$0.00
Exercise	Restricted Stock Units	8,750	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	119,520	$0.00	$0.00
Exercise	Common Stock	42,083	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	11,570	$4.24	$49K
holding	Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct); Stock Option (Right to Buy) — 119,520 shares (Direct); Common Stock — 82,594 shares (Direct); Common Stock — 82,508 shares (Indirect, Held by John Vavricka as the Trustee of the John F. Vavricka Deed of Trust)

Footnotes (4)

F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2. The original grant of 100,000 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026.
F3. Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026.
F4. The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2026 such that the option is fully vested on January 31, 2030.

FAQ

What insider transactions did Atea Pharmaceuticals (AVIR) report for John Vavricka?

Atea’s Chief Commercial Officer John Vavricka acquired 42,083 common shares from RSU settlements and had 11,570 shares withheld for taxes at $4.24. He also received 119,520 new stock options and now holds common stock both directly and through a personal trust.

How many Atea (AVIR) shares does John Vavricka own after this Form 4?

After the reported transactions, John Vavricka directly owns 82,594 Atea common shares. In addition, he indirectly holds 82,508 shares as trustee of the John F. Vavricka Deed of Trust, giving him significant combined exposure to Atea’s equity.

What stock options did Atea’s CCO receive according to this Form 4?

The filing shows Vavricka was granted 119,520 stock options with a $4.24 exercise price. These options vest in 48 equal monthly installments following January 31, 2026, and will be fully vested by January 31, 2030, aligning incentives over a multi-year period.

What happened to John Vavricka’s restricted stock units in Atea (AVIR)?

Previously granted RSUs, including 33,333 time-based units and 8,750 performance-based units, vested and were settled into common stock on January 31, 2026. After these conversions, the reported RSU balances are zero, meaning all those specific awards have fully vested.

Why were 11,570 Atea (AVIR) shares reported with code "F" on the Form 4?

The 11,570 common shares reported with transaction code “F” were withheld at $4.24 per share, typically to satisfy tax withholding obligations upon RSU vesting. This reduced the net shares delivered to Vavricka while meeting required tax payments in stock.

How do the new Atea stock options for Vavricka vest over time?

The 119,520 stock options vest in forty-eight equal monthly installments after January 31, 2026. According to the filing, this means the grant becomes fully exercisable on January 31, 2030, creating a long-term incentive structure for Atea’s Chief Commercial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/03/2026 - 07:47 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vavricka John

(Last)

(First)

(Middle)

225 FRANKLIN STREET

SUITE 2100

(Street)

BOSTON

02110

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Atea Pharmaceuticals, Inc. [ AVIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/31/2026		M		42,083	A	⁽¹⁾	94,164	D
Common Stock	01/31/2026		F		11,570	D	$4.24	82,594	D
Common Stock								82,508	I	Held by John Vavricka as the Trustee of the John F. Vavricka Deed of Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	01/31/2026		M			33,333	⁽²⁾	⁽²⁾	Common Stock	33,333	$0	0	D
Restricted Stock Units	⁽¹⁾	01/31/2026		M			8,750	⁽³⁾	⁽³⁾	Common Stock	8,750	$0	0	D
Stock Option (Right to Buy)	$4.24	01/31/2026		A		119,520		⁽⁴⁾	01/30/2036	Common Stock	119,520	$0	119,520	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2. The original grant of 100,000 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026.

3. Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026.

4. The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2026 such that the option is fully vested on January 31, 2030.

	/s/ Andrea Corcoran, as Attorney-in-Fact for John Vavricka	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR